scholarly journals Ten yr of pediatric heart transplantation: A report from the Pediatric Heart Transplant Study

2013 ◽  
Vol 17 (2) ◽  
pp. 99-111 ◽  
Author(s):  
Anne I. Dipchand ◽  
Richard Kirk ◽  
William T. Mahle ◽  
Margaret A. Tresler ◽  
David C. Naftel ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Heart Transplant ◽  
Pediatric Heart Transplantation ◽  
Pediatric Heart Transplant

New‐onset diabetes after pediatric heart transplantation: A review of the Pediatric Heart Transplant Study

2019 ◽  
Vol 23 (5) ◽  
Author(s):  
Joshua D. Sparks ◽  
Ryan S. Cantor ◽  
Elizabeth Pruitt ◽  
James K. Kirklin ◽  
Michael Carboni ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Heart Transplant ◽  
Onset Diabetes ◽  
Pediatric Heart Transplantation ◽  
Pediatric Heart Transplant ◽  
New Onset

scholarly journals Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2

2014 ◽  
Vol 19 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Gilbert J. Burckart ◽  
William D. Figg ◽  
Maria M. Brooks ◽  
Dionna J. Green ◽  
Sarah M. Troutman ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Candidate Gene ◽  
Heart Transplant ◽  
Direct Sequencing ◽  
Outcome Data ◽  
Polymorphism Analysis ◽  
Racial Groups ◽  
Post Transplantation ◽  
Pediatric Heart Transplantation ◽  
Pediatric Heart Transplant

OBJECTIVES Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2. The ABCC2 rs717620 A allele has been associated with enterohepatic recirculation of MPA, and our previous work had correlated the discontinuance of MPA with this allele in pediatric heart transplant patients. Therefore, we hypothesized that the ABCC2 rs717620 A allele would be associated with poorer outcomes including rejection with hemodynamic compromise (RHC), graft failure, and death in the pediatric heart transplant (PHTx) population receiving MPA. METHODS PHTx recipients from 6 institutions in the Pediatric Heart Transplantation Study (PHTS) from the period of 1993–2009, receiving MPA therapy, were genotyped for ABCC2 rs717620. Genotyping was accomplished by direct sequencing. Demographic and outcome data were limited to the data routinely collected as part of the PHTS and included RHC and mortality. RESULTS Two hundred ninety patients were identified who received MPA at some point post transplantation, of which 200 carried the GG genotype, 81 carried the AG genotype, and 9 carried the AA genotype. Follow-up time after transplantation was 6 years. RHC occurred in 76 patients and 18 patients died. In the 281 patients followed up more than 1 year, late RHC (>1 year post transplantation) occurred in 42 patients. While both RHC and late RHC were associated with the ABCC2 rs717620 GG genotype (hazard ratios: 1.80 and 4.57, respectively, p<0.05) in all patients, this association was not significant in PHTx patients receiving only MPA as the antiproliferative agent from the time of transplant (n=142). CONCLUSIONS ABCC2 rs717620 polymorphisms varied within racial groups. As a candidate gene assessment, the ABCC2 rs717620 AG and AA genotypes may be associated with improved, rather than poorer, RHC in PHTx patients receiving MPA therapy. ABCC2 rs717620 polymorphisms should be included in any expanded pharmacogenomic analysis of outcomes after pediatric heart transplantation.

scholarly journals Sudden death after pediatric heart transplantation: Analysis of data from the Pediatric Heart Transplant Study Group

2011 ◽  
Vol 30 (12) ◽  
pp. 1395-1402 ◽  
Author(s):  
Kevin P. Daly ◽  
Sujata B. Chakravarti ◽  
Margaret Tresler ◽  
David C. Naftel ◽  
Elizabeth D. Blume ◽  
...  
Keyword(s):  
Sudden Death ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Study Group ◽  
Pediatric Heart Transplantation ◽  
Pediatric Heart Transplant

261 ABO-Incompatible Heart Transplantation in Infants: Analysis of the Pediatric Heart Transplant Study (PHTS) Database

2011 ◽  
Vol 30 (4) ◽  
pp. S92 ◽  
Author(s):  
H.T. Henderson ◽  
C.E. Canter ◽  
W.T. Mahle ◽  
A.I. Dipchand ◽  
K. LaPorte ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Heart Transplant ◽  
Pediatric Heart Transplant

Abstract 14040: Hospitalizations for Respiratory Syncytial Virus and Vaccine Preventable Infections Following Pediatric Heart Transplantation: A PHIS Database Analysis

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Emily A Hayes ◽  
Stephen Hart ◽  
Charitha Gowda ◽  
Deipanjan Nandi
Keyword(s):  
Risk Factors ◽  
Respiratory Syncytial Virus ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Immunosuppressive Agents ◽  
Circulatory Support ◽  
Transplant Recipients ◽  
Increased Risk ◽  
Pediatric Heart Transplantation ◽  
Syncytial Virus

Introduction: Despite improvements in pediatric heart transplant outcomes, respiratory syncytial virus (RSV) and vaccine preventable infections (R/VPI) are a major cause of morbidity and hospital resource use. The frequency and risk factors for hospitalizations due to R/VPI in heart transplant recipients are unknown. Methods: Patients ≤18 years who underwent heart transplantation at hospitals contributing to the Pediatric Health Information System database from 9/2003 to 12/2018 were identified. The transplant hospitalization and subsequent hospitalizations for R/VPI through 12/2018 were analyzed. Risk factors for R/VPI hospitalizations were evaluated using negative regression binomial models adjusted for potential demographic and clinical confounders. Total hospital costs were determined adjusted for 2018 US $. Results: Of 3,815 transplant recipients, 681 (17.9%) had a R/VPI hospitalization during 23,746 available person-years of follow-up after transplant. There were 984 R/VPIs diagnosed during 951 hospitalizations, and 440 (44.7%) occurred in the first year after transplant (Figure). The most common causes were RSV (n=380; 38.6%), influenza (n=265; 26.9%), and pneumococcus (n=105; 10.7%). In adjusted analyses, there was an increased risk of R/VPI hospitalization in patients requiring mechanical circulatory support prior to transplant, those who received induction with ≥ 2 immunosuppressive agents, and patients <2 years old. The median length of stay for a R/VPI hospitalization was 4 days (interquartile range [IQR]: 2-8 days) with a median total cost of $11,081 (IQR: $6,215 - $24,322). Conclusions: Hospitalization for R/VPIs occurred frequently following pediatric heart transplantation and were associated with significant cost. Potential strategies to minimize R/VPI could include expanding vaccine use through accelerated immunization schedules in younger patients and routine monitoring of immunogenicity after vaccination.

The Virtual Heart Transplant - The Next Step in Size Matching for Pediatric Heart Transplantation

2017 ◽  
Vol 36 (4) ◽  
pp. S165 ◽  
Author(s):  
J.D. Plasencia ◽  
J.R. Ryan ◽  
S.S. Park ◽  
J.J. Nigro ◽  
D.H. Frakes ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Heart Transplant ◽  
Pediatric Heart Transplantation
Sign in / Sign up

Export Citation Format

Share Document